Icecure Medical Ltd

Icecure Medical operates with a strong liquidity position, as evidenced by $10.97 million in cash and equivalents, which represents 68.3% of total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 3.39 suggests the company has sufficient short-term assets to cover its liabilities. Profitability metrics are negative, with a net loss of $3.61 million and an operating loss of $3.65 million. Return on equity is -31.02%, and return on assets is -22.48%, both significantly below the industry median for Advanced Medical Equipment & Technology. The company's gross margin of 36.2% is in line with industry norms, but operating and net margins are deeply negative. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks. No material revenue concentration by geography is reported, but the absence of segmental or geographic breakdowns limits visibility into operational resilience. Growth prospects are constrained by the current financial performance. The company reported $743,000 in revenue, with no disclosed year-over-year growth rate. Analysts have assigned a mean price target of $2.73, implying a 1,045% upside from the current market price of $0.241. However, the company's negative operating cash flow of $2.85 million and free cash flow of $3.55 million suggest ongoing operational challenges. Risk factors include the company's negative net income and operating income, which could pressure liquidity if cash burn accelerates. The dilution risk is currently low, with no immediate filing-based flags detected. However, the company's reliance on a single product line and lack of geographic diversification could expose it to regulatory or market-specific shocks. Recent events include the publication of the latest financial data and analyst price targets. No material filings or transcripts were disclosed in the provided data. The company's current market cap of $19.56 million is significantly below its enterprise value to revenue multiple of 11.57, suggesting a high valuation relative to current revenue.